Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2014-04-18

FDA Approved: EDARBYCLOR — Supplemental Application (Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals))

View source ↗

Summary

The FDA approved a supplemental application for EDARBYCLOR (azilsartan medoxomil and chlorthalidone) submitted by Azurity Pharmaceuticals, likely updating the p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EDARBYCLOR (AZILSARTAN KAMEDOXOMIL AND CHLORTHALIDONE)

Snippet

SUPPL AP for EDARBYCLOR (AZILSARTAN KAMEDOXOMIL AND CHLORTHALIDONE)